Novartis has raised its growth and margin targets for the year following a strong annual report, marking the third increase in financial targets this year. Analysts had anticipated a further rise in margin targets, but consensus estimates are expected to remain largely unchanged.
Novartis AG has raised its annual profit forecast for the third consecutive quarter, driven by strong sales of its psoriasis and cancer medications. The company now expects core operating income to increase by a high-teens percentage, with sales projected to grow by low double digits, both at the upper end of previous guidance.
The SMI closed lower, impacted by a decline in Novartis shares, while Wall Street remained subdued. In contrast, Trump Media & Technology's stock surged by 12% to over $54 amid speculation of Donald Trump's potential presidential win, reaching its highest level since March. Despite Trump's rising poll numbers, the race remains tight in key battleground states.
The global small-molecule injectable drugs market reached $188.9 billion in 2021, with a projected growth rate of 8% CAGR, expected to hit $837.8 billion by 2030. North America leads the market with a 37% share, driven by increased R&D and product approvals, while Europe is anticipated to grow the fastest due to rising demand for minimally invasive procedures. Intravenous injections accounted for 30% of the market, highlighting their critical role in rapid drug administration.
The bile duct cancer market is expanding, driven by a shortage of specialists and healthcare system challenges in developing countries. In 2021, North America led the market with a 37.1% share and $185.4 billion in revenue, fueled by increased R&D and rising cancer prevalence. The Asia-Pacific region is projected to grow the fastest through 2030, supported by awareness programs and private investments.
Migros plans to reduce prices on over 1,000 products by 2025 to regain market share from discounters like Aldi and Lidl, alongside opening 140 new stores by 2030 with a CHF 2 billion investment. The Zurich University of the Arts has ended its partnership with a military-affiliated Chinese university due to legal and operational concerns. Volkswagen is set to close three plants in Germany, risking tens of thousands of jobs, while Donald Trump faced backlash for controversial remarks during a New York campaign event. Gérard Depardieu's sexual harassment trial has been postponed due to health issues, with a new court date set for March.
Novartis has entered a $150 million deal with Monte Rosa Therapeutics to develop molecular glue degraders targeting the immune signaling protein VAV1, which is considered "undruggable." The partnership could yield up to $2.1 billion in additional payments based on development milestones. Monte Rosa will complete the ongoing Phase 1 study of MRT-6160, while Novartis will manage further development, with both companies sharing profits and losses from commercialization.
This week marks a significant period in the third quarter reporting season, starting with Rieter's investor day on Monday. Key healthcare companies, including Novartis and Idorsia, will report on Tuesday, alongside Straumann and Clariant, while UBS and Sunrise are set to present their results on Wednesday. The week continues with Geberit and Swisscom on Thursday, as various companies navigate challenges and opportunities in their respective sectors.
In 2023, CEO salaries in Switzerland rose by an average of 5%, with UBS CEO Sergio Ermotti leading at CHF 14.5 million for just nine months in office. Following him were Novartis CEO Vas Narasimhan at CHF 13.3 million and former Nestlé CEO Mark Schneider at CHF 11.2 million. Despite public discontent over high executive pay, total remuneration for SMI CEOs has increased by a quarter over the past three years.
The global diabetic retinopathy devices market, valued at USD 12.47 billion in 2022, is projected to grow at a robust CAGR of around 30% through 2030, driven by rising diabetes cases and an aging population. Non-proliferative diabetic retinopathy is expected to dominate, while North America will lead regionally, with significant contributions from the APAC region due to its large diabetic population. Key players include F. Hoffmann-La Roche, Novartis, and Regeneron, focusing on innovative treatments and technologies.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
